MNKD Mannkind Corp
- Stocks
- Healthcare
- NASDAQ: MNKD
Price (delayed)
$6.06
Market cap
$1.86B
P/E Ratio
55.09
Dividend/share
N/A
EPS
$0.11
Enterprise value
$2.09B
Relative Growth:
Rel. Growth:
85
Relative Strength:
Rel. Strength:
76
Relative Valuation:
Rel. Valuation:
43
Relative Profitability:
Rel. Profitability:
71
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its
Highlights
Mannkind's net income has soared by 179% YoY and by 9% from the previous quarter
Mannkind's EPS has soared by 120% YoY and by 10% from the previous quarter
Mannkind's quick ratio has decreased by 46% YoY
Key stats
What are the main financial stats of MNKD
Market
Valuations
Earnings
Shares outstanding
306.83M
Market cap
$1.86B
Enterprise value
$2.09B
Price to earnings (P/E)
55.09
Price to book (P/B)
N/A
Price to sales (P/S)
6.12
PEG
0.46
EV/EBIT
30.49
EV/EBITDA
26.41
EV/Sales
6.92
Revenue
$301.74M
Gross profit
$226.03M
Operating income
$72.74M
Net income
$32.8M
EBIT
$68.54M
EBITDA
$79.1M
Free cash flow
$28.79M
Per share
Balance sheet
Liquidity
EPS
$0.11
EPS diluted
$0.11
Free cash flow per share
$0.09
Book value per share
-$0.18
Revenue per share
$0.99
TBVPS
$1.33
Total assets
$411.7M
Total liabilities
$466.74M
Debt
$287.72M
Equity
-$55.04M
Working capital
$167.2M
Debt to equity
-5.23
Current ratio
2.5
Quick ratio
1.85
Net debt/EBITDA
2.91
Margins
Efficiency
Dividend
EBITDA margin
26.2%
Gross margin
74.9%
Net margin
10.9%
Operating margin
24.1%
Return on assets
7.8%
Return on equity
N/A
Return on invested capital
11.4%
Return on capital employed
22.9%
Return on sales
22.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNKD stock price
How has the Mannkind stock price performed over time
Intraday
10.58%
1 week
9.39%
1 month
5.21%
1 year
-16.53%
YTD
-5.75%
QTD
12.85%
Financial performance
How have Mannkind's revenue and profit performed over time
Revenue
$301.74M
Gross profit
$226.03M
Operating income
$72.74M
Net income
$32.8M
Gross margin
74.9%
Net margin
10.9%
Mannkind's net income has soared by 179% YoY and by 9% from the previous quarter
The company's net margin has surged by 132% YoY and by 8% QoQ
MNKD's operating income has soared by 61% YoY but it is down by 7% QoQ
MNKD's operating margin is up by 33% year-on-year but it is down by 8% since the previous quarter
Price vs fundamentals
How does MNKD's price correlate with its fundamentals
Growth
What is Mannkind's growth rate over time
Valuation
What is Mannkind stock price valuation
P/E
55.09
P/B
N/A
P/S
6.12
EV/EBIT
30.49
EV/EBITDA
26.41
EV/Sales
6.92
Mannkind's EPS has soared by 120% YoY and by 10% from the previous quarter
The price to earnings (P/E) is 3% lower than the last 4 quarters average of 56.8
The equity has surged by 76% year-on-year and by 6% since the previous quarter
The P/S is 36% lower than the 5-year quarterly average of 9.6 but 13% higher than the last 4 quarters average of 5.4
The revenue has grown by 21% YoY
Efficiency
How efficient is Mannkind business performance
The ROA has soared by 189% YoY and by 11% QoQ
The company's return on invested capital has surged by 58% YoY and by 2.7% QoQ
Mannkind's ROS has increased by 21% YoY but it has decreased by 7% from the previous quarter
Dividends
What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNKD.
Financial health
How did Mannkind financials performed over time
The company's total assets is 12% lower than its total liabilities
Mannkind's quick ratio has decreased by 46% YoY
The company's current ratio fell by 39% YoY but it rose by 6% QoQ
The debt to equity has dropped by 151% year-on-year and by 6% since the previous quarter
The equity has surged by 76% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.